Biodesix director exercises 1,361 RSUs to shares
Biodesix Inc. director and chairman John Patience reported a routine equity compensation transaction involving restricted stock units (RSUs) that converted into common shares.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Biodesix Inc. director and chairman John Patience reported a routine equity compensation transaction involving restricted stock units (RSUs) that converted into common shares. On June 30, 2026, he exercised 1,361 RSUs, receiving 1,361 shares of common stock, increasing his direct common stock holdings to 25,383 shares.
Following the transaction, he also directly holds 2,721 RSUs, each representing a contingent right to one share of common stock. These RSUs vest in four substantially equal installments on March 31, June 30, September 30 and December 31, 2026, generally subject to his continued service with Biodesix. The filing also lists indirect holdings of common stock held by his spouse, the John Patience Living Trust dated July 23, 1993, and Patience Enterprises LP.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Restricted Stock Units | 1,361 | $0.00 | $0.00 |
| Exercise | Common Stock | 1,361 | $0.00 | $0.00 |
| Holding | Common Stock | -- | -- | -- |
| Holding | Common Stock | -- | -- | -- |
| Holding | Common Stock | -- | -- | -- |
Footnotes (4)
- F1. Each restricted stock unit (the "RSU") represents a contingent right to receive one share of the Issuer's common stock ("Common Stock").
- F2. The Reporting Person is the sole general partner of Patience Enterprises LP. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 or for any other purpose.
- F3. The Reporting Person is the sole trustee of John Patience Living Trust (July 23, 1993).
- F4. These RSUs vest in four substantially equal installments on March 31, June 30, September 30 and December 31, 2026, generally subject to the Reporting Person's continued service with the Issuer, and have no expiration date.
Key Figures
Key Terms
Restricted Stock Units financial
pecuniary interest financial
beneficial ownership financial
Section 16 regulatory
vesting financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Biodesix (BDSX) director John Patience report in this Form 4?
What is the vesting schedule for John Patience’s 2026 Biodesix RSUs?
Does this Biodesix (BDSX) Form 4 show any open‑market stock purchases or sales?
What indirect Biodesix holdings are associated with John Patience in this Form 4?
How many restricted stock units does John Patience hold after the June 30, 2026 transaction?
AI-generated analysis. How Rhea-AI works. Not financial advice.